SI1002795T1 - HIV Replication inhibiting pyrimidines - Google Patents
HIV Replication inhibiting pyrimidinesInfo
- Publication number
- SI1002795T1 SI1002795T1 SI9930275T SI9930275T SI1002795T1 SI 1002795 T1 SI1002795 T1 SI 1002795T1 SI 9930275 T SI9930275 T SI 9930275T SI 9930275 T SI9930275 T SI 9930275T SI 1002795 T1 SI1002795 T1 SI 1002795T1
- Authority
- SI
- Slovenia
- Prior art keywords
- hiv replication
- replication inhibiting
- inhibiting pyrimidines
- pyrimidines
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10779298P | 1998-11-10 | 1998-11-10 | |
US14396299P | 1999-07-15 | 1999-07-15 | |
PCT/EP1999/007417 WO2000027825A1 (en) | 1998-11-10 | 1999-09-24 | Hiv replication inhibiting pyrimidines |
EP99203590A EP1002795B1 (en) | 1998-11-10 | 1999-11-01 | HIV Replication inhibiting pyrimidines |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1002795T1 true SI1002795T1 (en) | 2003-10-31 |
Family
ID=26805159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9930275T SI1002795T1 (en) | 1998-11-10 | 1999-11-01 | HIV Replication inhibiting pyrimidines |
Country Status (41)
Country | Link |
---|---|
US (5) | US6878717B2 (pt) |
EP (2) | EP1002795B1 (pt) |
JP (1) | JP3635238B2 (pt) |
KR (1) | KR100658489B1 (pt) |
CN (1) | CN1214013C (pt) |
AP (1) | AP1683A (pt) |
AR (1) | AR024227A1 (pt) |
AT (2) | ATE233740T1 (pt) |
AU (2) | AU762523C (pt) |
BG (1) | BG65103B1 (pt) |
BR (1) | BRPI9915552B8 (pt) |
CA (1) | CA2350801C (pt) |
CY (1) | CY2008021I2 (pt) |
CZ (1) | CZ301367B6 (pt) |
DE (3) | DE122009000003I1 (pt) |
DK (1) | DK1002795T3 (pt) |
EA (1) | EA004049B1 (pt) |
EE (1) | EE05086B1 (pt) |
ES (2) | ES2193664T3 (pt) |
FR (1) | FR09C0004I2 (pt) |
HK (2) | HK1025330A1 (pt) |
HR (2) | HRP20010161B9 (pt) |
HU (2) | HU227453B1 (pt) |
ID (1) | ID28376A (pt) |
IL (2) | IL143023A0 (pt) |
LT (1) | LTC1002795I2 (pt) |
LU (1) | LU91528I2 (pt) |
MY (1) | MY121108A (pt) |
NL (1) | NL300373I2 (pt) |
NO (3) | NO318801B1 (pt) |
NZ (1) | NZ511116A (pt) |
OA (1) | OA11674A (pt) |
PL (1) | PL204427B1 (pt) |
PT (1) | PT1002795E (pt) |
SI (1) | SI1002795T1 (pt) |
SK (2) | SK287270B6 (pt) |
TR (1) | TR200101306T2 (pt) |
TW (1) | TWI238161B (pt) |
UA (1) | UA70966C2 (pt) |
WO (1) | WO2000027825A1 (pt) |
ZA (1) | ZA200103769B (pt) |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI9915552B8 (pt) * | 1998-11-10 | 2021-05-25 | Janssen Pharmaceutica Nv | pirimidinas inibidoras da reprodução do hiv |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
SK285240B6 (sk) | 1999-09-24 | 2006-09-07 | Janssen Pharmaceutica N. V. | Antivírusové prostriedky |
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
JP2003511378A (ja) | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
CN1429222A (zh) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
DK1282607T3 (en) | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
EP1282606B1 (en) | 2000-05-08 | 2015-04-22 | Janssen Pharmaceutica NV | Hiv replication inhibiting pyrimidines and triazines |
CA2429364C (en) * | 2000-11-01 | 2007-01-02 | Snapnames.Com, Inc. | Domain name acquisition and management system and method |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
UY27487A1 (es) * | 2001-10-17 | 2003-05-30 | Boehringer Ingelheim Pharma | Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
CA2463822A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
WO2003037869A1 (en) | 2001-11-01 | 2003-05-08 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA04007776A (es) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa. |
OA12790A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
CN1290893C (zh) * | 2002-05-03 | 2006-12-20 | 詹森药业有限公司 | 聚合物微乳状液 |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
TW200409629A (en) | 2002-06-27 | 2004-06-16 | Bristol Myers Squibb Co | 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
EP2422772A3 (en) * | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
MXPA05005547A (es) * | 2002-11-28 | 2005-07-26 | Schering Ag | Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos. |
DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
WO2004074266A1 (en) * | 2003-02-07 | 2004-09-02 | Janssen Pharmaceutica N.V. | Hiv inhibiting 1,2,4-triazines |
ES2325440T3 (es) * | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
KR101201603B1 (ko) | 2003-07-30 | 2012-11-14 | 리겔 파마슈티칼스, 인크. | 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물 |
CN100475815C (zh) * | 2003-09-25 | 2009-04-08 | 詹森药业有限公司 | 抑制hiv复制的嘌呤衍生物 |
US8099262B2 (en) | 2004-03-02 | 2012-01-17 | Virco Bvba | Estimation of clinical cut-offs |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
WO2006010750A1 (en) | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
US7923554B2 (en) | 2004-08-10 | 2011-04-12 | Janssen Pharmaceutica N.V. | HIV inhibiting 1,2,4-triazin-6-one derivatives |
US7531548B2 (en) | 2004-09-30 | 2009-05-12 | Tibotec Pharmaceuticals Ltd | HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
CN101027288B (zh) * | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
AU2005288864B2 (en) | 2004-09-30 | 2012-08-23 | Janssen Sciences Ireland Uc | HIV inhibiting 5-heterocyclyl pyrimidines |
CA2577588C (en) | 2004-10-29 | 2013-09-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting bicyclic pyrimidine derivatives |
JP2008519073A (ja) * | 2004-11-08 | 2008-06-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビル及びエトラビリンの同時投与によるhiv感染症の治療法 |
EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
ATE451381T1 (de) | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
CN101107234B (zh) * | 2005-01-27 | 2013-06-19 | 泰博特克药品有限公司 | 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 |
KR101362621B1 (ko) | 2005-02-16 | 2014-02-13 | 아스트라제네카 아베 | 화합물 |
BRPI0607811B8 (pt) * | 2005-02-18 | 2021-05-25 | Janssen R & D Ireland | derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso |
DE602006015291D1 (de) | 2005-03-04 | 2010-08-19 | Little Island Co Cork | Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine |
AU2006248780B2 (en) | 2005-05-16 | 2010-06-03 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2006125809A1 (en) | 2005-05-26 | 2006-11-30 | Tibotec Pharmaceuticals Ltd | Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
KR20080059634A (ko) * | 2005-10-06 | 2008-06-30 | 유니버시티 오브 매사추세츠 | Hiv 복제를 억제하기 위한 시약의 조성물 및 합성법 |
PT1945631E (pt) | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
JP5137849B2 (ja) | 2006-01-19 | 2013-02-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体 |
DK1981874T3 (da) | 2006-01-19 | 2009-09-28 | Janssen Pharmactuica N V | Aminophenylderivater som nye inhibitorer af histondeacetylase |
WO2007082874A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2004632B1 (en) * | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
CN101410394B (zh) | 2006-03-30 | 2012-02-08 | 泰博特克药品有限公司 | 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 |
US8623887B2 (en) | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
ME01305B (me) * | 2006-06-06 | 2012-04-30 | Tibotec Pharm Ltd | Proces za pripremanje raspršivanjem osušenih formulacija tmc125 |
HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical preparations |
WO2008063301A2 (en) * | 2006-10-11 | 2008-05-29 | Alpharma, Inc. | Pharmaceutical compositions |
WO2008068299A2 (en) | 2006-12-06 | 2008-06-12 | Tibotec Pharmaceuticals Ltd. | Hydrobromide salt of an anti-hiv compound |
AU2007341228B2 (en) | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
BRPI0720858B8 (pt) * | 2006-12-29 | 2021-05-25 | Janssen R & D Ireland | pirimidinas 6-substituídas inibidoras de hiv e composição farmacêutica que as compreende |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
JP5748737B2 (ja) | 2009-03-30 | 2015-07-15 | ヤンセン・アールアンドデイ・アイルランド | エトラビリンとニコチンアミドの共結晶 |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
EP2342186B1 (en) | 2009-06-22 | 2014-09-17 | Emcure Pharmaceuticals Limited | Process for synthesis of etravirine |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
CA2803848A1 (en) | 2010-06-28 | 2012-01-05 | Hetero Research Foundation | A process for etravirine intermediate and polymorphs of etravirine |
MY160734A (en) | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
NZ710636A (en) | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
HUE037844T2 (hu) | 2010-11-10 | 2018-09-28 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
WO2012147104A1 (en) | 2011-04-26 | 2012-11-01 | Mylan Laboratories Ltd | Novel process for the preparation of etravirine |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2012170647A1 (en) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
EP2748166B1 (en) | 2011-08-23 | 2018-07-11 | Asana BioSciences, LLC | Pyrimido-pyridazinone compounds and use thereof |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法 |
WO2013109354A2 (en) * | 2011-12-07 | 2013-07-25 | Texas Southern University | Etravirine formulations and uses thereof |
ES2880109T3 (es) | 2012-03-15 | 2021-11-23 | Celgene Car Llc | Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico |
CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US20150336900A1 (en) * | 2012-10-29 | 2015-11-26 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the Synthesis of Etravirine and Its Intermediates |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
JP6370801B2 (ja) | 2012-12-21 | 2018-08-08 | ベルリクス・ファーマ・インコーポレイテッド | 肝疾患または肝障害の治療のための使用および方法 |
KR20150119012A (ko) | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
DK3179858T3 (da) | 2014-08-13 | 2019-07-22 | Celgene Car Llc | Forme og sammensætninger af en ERK-inhibitor |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
CN104926829A (zh) * | 2015-06-08 | 2015-09-23 | 山东大学 | 一种噻吩并嘧啶类衍生物及其制备方法和应用 |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
CN110066273A (zh) * | 2019-06-05 | 2019-07-30 | 山东大学 | 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
CN111217833B (zh) * | 2020-02-21 | 2021-03-16 | 山东大学 | 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用 |
CN111875548A (zh) * | 2020-07-16 | 2020-11-03 | 山东大学 | 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US4659363A (en) * | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
DE3581570D1 (de) * | 1984-06-25 | 1991-03-07 | Ciba Geigy Ag | Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel. |
ES2013664A6 (es) | 1988-03-31 | 1990-05-16 | Mitsubishi Chem Ind | Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6. |
JPH02308248A (ja) | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
JP2895680B2 (ja) * | 1992-07-08 | 1999-05-24 | シャープ株式会社 | 磁気ヘッドおよびその製造方法 |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
CZ154398A3 (cs) | 1995-11-23 | 1998-08-12 | Janssen Pharmaceutica N.V. | Pevné směsi cyklodextrinů připravené vytlačováním taveniny |
KR100219922B1 (ko) * | 1996-05-16 | 1999-09-01 | 이서봉 | 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법 |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
DE29704863U1 (de) * | 1997-03-17 | 1997-05-22 | Ges Innenhochdruckverfahren | Achsschwinge |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
ATE232521T1 (de) * | 1998-03-27 | 2003-02-15 | Janssen Pharmaceutica Nv | Hiv hemmende pyrimidin derivate |
KR100643419B1 (ko) * | 1998-03-27 | 2006-11-10 | 얀센 파마슈티카 엔.브이. | Hiv를 억제하는 피리미딘 유도체 |
BRPI9915552B8 (pt) * | 1998-11-10 | 2021-05-25 | Janssen Pharmaceutica Nv | pirimidinas inibidoras da reprodução do hiv |
DK1282607T3 (en) * | 2000-05-08 | 2016-02-01 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
-
1999
- 1999-09-24 BR BRPI9915552A patent/BRPI9915552B8/pt not_active IP Right Cessation
- 1999-09-24 AP APAP/P/2001/002121A patent/AP1683A/en active
- 1999-09-24 SK SK5012-2009A patent/SK287270B6/sk not_active IP Right Cessation
- 1999-09-24 UA UA2001042857A patent/UA70966C2/uk unknown
- 1999-09-24 HU HU0104177A patent/HU227453B1/hu active Protection Beyond IP Right Term
- 1999-09-24 KR KR1020017003576A patent/KR100658489B1/ko active IP Right Grant
- 1999-09-24 NZ NZ511116A patent/NZ511116A/en not_active IP Right Cessation
- 1999-09-24 EA EA200100536A patent/EA004049B1/ru active IP Right Revival
- 1999-09-24 CA CA002350801A patent/CA2350801C/en not_active Expired - Lifetime
- 1999-09-24 HU HU1100091A patent/HU230394B1/hu unknown
- 1999-09-24 AU AU62008/99A patent/AU762523C/en not_active Revoked
- 1999-09-24 ID IDW00200101015A patent/ID28376A/id unknown
- 1999-09-24 CN CNB998119180A patent/CN1214013C/zh not_active Expired - Lifetime
- 1999-09-24 OA OA1200100113A patent/OA11674A/en unknown
- 1999-09-24 WO PCT/EP1999/007417 patent/WO2000027825A1/en active Application Filing
- 1999-09-24 PL PL347586A patent/PL204427B1/pl unknown
- 1999-09-24 EE EEP200100252A patent/EE05086B1/xx active Protection Beyond IP Right Term
- 1999-09-24 TR TR2001/01306T patent/TR200101306T2/xx unknown
- 1999-09-24 JP JP2000581005A patent/JP3635238B2/ja not_active Expired - Lifetime
- 1999-09-24 IL IL14302399A patent/IL143023A0/xx active Protection Beyond IP Right Term
- 1999-09-24 SK SK603-2001A patent/SK287269B6/sk active Protection Beyond IP Right Term
- 1999-09-24 CZ CZ20011533A patent/CZ301367B6/cs not_active IP Right Cessation
- 1999-11-01 US US09/430,966 patent/US6878717B2/en not_active Expired - Lifetime
- 1999-11-01 AT AT99203590T patent/ATE233740T1/de active
- 1999-11-01 DE DE122009000003C patent/DE122009000003I1/de active Pending
- 1999-11-01 PT PT99203590T patent/PT1002795E/pt unknown
- 1999-11-01 DK DK99203590T patent/DK1002795T3/da active
- 1999-11-01 EP EP99203590A patent/EP1002795B1/en not_active Expired - Lifetime
- 1999-11-01 EP EP02018455A patent/EP1270560B1/en not_active Expired - Lifetime
- 1999-11-01 DE DE69941934T patent/DE69941934D1/de not_active Expired - Lifetime
- 1999-11-01 ES ES99203590T patent/ES2193664T3/es not_active Expired - Lifetime
- 1999-11-01 DE DE69905683T patent/DE69905683T2/de not_active Expired - Lifetime
- 1999-11-01 AT AT02018455T patent/ATE455107T1/de not_active IP Right Cessation
- 1999-11-01 SI SI9930275T patent/SI1002795T1/xx unknown
- 1999-11-01 ES ES02018455T patent/ES2338760T3/es not_active Expired - Lifetime
- 1999-11-05 MY MYPI99004805A patent/MY121108A/en unknown
- 1999-11-09 AR ARP990105680A patent/AR024227A1/es active IP Right Grant
- 1999-12-23 TW TW088119614A patent/TWI238161B/zh not_active IP Right Cessation
-
2000
- 2000-07-26 HK HK00104633A patent/HK1025330A1/xx not_active IP Right Cessation
-
2001
- 2001-03-07 HR HRP20010161AA patent/HRP20010161B9/hr not_active IP Right Cessation
- 2001-04-04 NO NO20011696A patent/NO318801B1/no not_active IP Right Cessation
- 2001-04-06 BG BG105418A patent/BG65103B1/bg unknown
- 2001-05-09 ZA ZA200103769A patent/ZA200103769B/en unknown
-
2003
- 2003-02-14 HK HK03101063.7A patent/HK1048817B/zh not_active IP Right Cessation
- 2003-08-05 US US10/634,682 patent/US7037917B2/en not_active Expired - Lifetime
-
2005
- 2005-07-28 IL IL169949A patent/IL169949A/en not_active IP Right Cessation
- 2005-08-16 US US11/204,513 patent/US20050288278A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/930,835 patent/US8003789B2/en not_active Expired - Fee Related
-
2008
- 2008-07-17 HR HRP20080359AA patent/HRP20080359B1/hr not_active IP Right Cessation
- 2008-12-03 LT LTPA2008016C patent/LTC1002795I2/lt unknown
- 2008-12-10 CY CY2008021C patent/CY2008021I2/el unknown
-
2009
- 2009-01-13 NL NL300373C patent/NL300373I2/nl unknown
- 2009-01-22 FR FR09C0004C patent/FR09C0004I2/fr active Active
- 2009-02-18 LU LU91528C patent/LU91528I2/fr unknown
- 2009-02-23 NO NO2009003C patent/NO2009003I2/no unknown
-
2011
- 2011-02-18 AU AU2011200708A patent/AU2011200708A1/en active Pending
- 2011-07-06 US US13/177,188 patent/US8530655B2/en not_active Expired - Fee Related
-
2021
- 2021-03-29 NO NO2021015C patent/NO2021015I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1025330A1 (en) | Hiv replication inhibiting pyrimidines | |
PL343196A1 (en) | Hiv inhibiting pyrimidine derivatives | |
EG24684A (en) | HIV replication inhibiting pyrimidines | |
DE59902573D1 (en) | Dihydropyrimidine | |
IL153754A0 (en) | Pyrimidine derivatives | |
AU1041802A (en) | Tetrahydro-heterocycloazepinyl pyrimidine derivatives | |
HK1078079A1 (en) | Pyrimidine derivatives | |
ZA992322B (en) | Phosphodiesterase iv-inhibiting diazepinoindoles. | |
MXPA03000504A (es) | Derivados de pirimidina. | |
DE69940886D1 (en) | Hiv impfstoff | |
IL166937A (en) | Uracil compounds | |
ZA200007155B (en) | Uracil compounds and use thereof. | |
ZA200100906B (en) | Uracil compounds and use thereof. | |
EP0954316A4 (en) | PYRIMIDINE DERIVATIVES | |
IL150715A0 (en) | Substituted pyrimidines | |
GB9810027D0 (en) | Incinerator | |
SI1303496T1 (sl) | Pirimidinski derivati |